Dr. Ramakrishnan Gopalakrishnan

Department of Medicine

University of Southern California, USA

Research Scientist

Email: ramankrg@med.usc.edu

Qualifications

1. Gopalakrishnan R, Matta H, Tolani B, Tim Triche Jr., and Chaudhary PM. Immunomodulatory drugs IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2015 Jun 29. doi: 10.1038/onc.2015.245.
2. Tolani B, Matta H, Gopalakrishnan R, Punj V, Chaudhary PM. NEMO is essential for KSHV-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death and its N-terminal 251 residues are sufficient for this process. J Virol. 2014, Jun; 88(11): 6345-54.
3. Sundaram J, Keshava S, Gopalakrishnan R, Esmon CT, Pendurthi UR, Rao LVM. Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivo. J Thromb Haemost. 2014 May, 12(5): 690-700.
4. Gopalakrishnan R, Matta H and Chaudhary PM. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV associated Primary Effusion Lymphoma and blcoks vFLIP K13-induced NF-κB. Clin Cancer Res. 2013 Sep 15, 19(18): 5016-26.
5. Tolani B, Gopalakrishnan R, Punj V, Matta H and Chaudhary PM. Targeting Myc in KSHV-associated Primary effusion lymphoma with BET bromodomain inhibitors. Oncogene, 2014 May 29; 33(22): 2928-37.
6. Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol Cell Biochem. 2013 May; 377(1-2):163-76.
7. Gopalakrishnan R, Pendurthi UR, Hedner U, Agersø H, Esmon CT and Rao LV. Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa. J Thromb Haemost. 2012 May; 10(5): 971-3.
8. Matta H,  Gopalakrishnan R, Graham C, Tolani B, Khanna A, Yi H, Suo Y, Chaudhary PM. Kaposi's Sarcoma Associated Herpesvirus Encoded Viral FLICE Inhibitory Protein K13 Activates NF-κB Pathway Independent of TRAF6, TAK1 and LUBAC. PLoS One. 2012; 7(5): e36601. Epub 2012 May 8.
9. Sen P, Clark CA, Gopalakrishnan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV. Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems. Thromb Haemost. 2012 May; 107(5): 951-61.
10. Sen P, Nayak R, Clark CA, Gopalakrishnan R, Esmon CT, Pendurthi UR, Rao LV. Factor X binding to endothelial cell protein C receptor: comparison with factor VIIa and activated protein C. Blood. 2011; 118(9): 2635-6.
11. Yang Y, Groshong JS, Matta H, Gopalakrishnan R, Yi H, Chaudhary PM. Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells. J Biol Chem. 2011 Aug 12; 286(32): 27988-97.
12. Matta H, Gopalakrishnan R, Punj V, Yi H, Suo Y, Chaudhary PM. A20 is induced by Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner. J Biol Chem. 2011 Jun 17;286(24):21555-64.
13. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT, Pendurthi UR, Rao LV. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood. 2011 Mar 17; 117(11):3199-208.
14. Gopalakrishnan R, Hedner U, Clark C, Pendurthi UR, Rao LV. rFVIIa transported from the blood stream into tissues is functionally active. J Thromb Haemost. 2010 Oct; 8(10): 2318-21.
15. Gopalakrishnan R, Hedner U, Ghosh S, Nayak RC, Allen TC, Pendurthi UR and Rao LV. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost. 2010; 8(2): 301-10.
16. Nayak RC, Sen P, Ghosh S, Gopalakrishnan R, Esmon CT, Pendurthi UR and Rao LV. Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications. Blood. 2009; 114(9): 1974-86.
17. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Devaki T. Capsaicin provokes apoptosis and restricts benzo(a)pyrene induced lung tumorigenesis in Swiss albino mice. Int Immunopharmacol. 2013 Oct; 17(2): 254-9.
18. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Asokkumar S, Naveenkumar C, Raghunandhakumar S, Devaki T. Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model. Inflamm Res. 2012 Nov; 61(11): 1169-75.
19. Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G, Devaki T. Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Eur J Pharmacol. 2010 Dec 15; 649(1-3): 320-7.
20. Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G, Devaki T. Hesperidin attenuates mitochondrial dysfunction during benzo(a)pyrene-induced lung carcinogenesis in mice. Fundam Clin Pharmacol. 2011 Feb; 25(1): 91-8.
21. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Naveenkumar C, Asokkumar S, Devaki T. Capsaicin alleviates the imbalance in xenobiotic metabolizing enzymes and tumor markers during experimental lung tumorigenesis. Mol Cell Biochem. 2009 Nov; 331(1-2): 135-43.
22. Anandakumar P, Kamaraj S, Ramakrishnan G, Jagan S, Devaki T. Chemopreventive task of capsaicin against benzo(a)pyrene-induced lung cancer in Swiss albino mice. Basic Clin Pharmacol Toxicol. 2009 May; 104(5): 360-5.
23. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009; 42(2): 229-40.
24. Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice. Invest New Drugs. 2009 Jun ;27(3): 214-22.
25. Ramakrishnan G, Jagan S, Kamaraj S, Anandakumar P, Devaki T. Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest New Drugs. 2009 Jun; 27(3): 233-40.

Profile Details